key: cord-1037064-jlg8xvc3 authors: Cueto-Robledo, Guillermo; Porres-Aguilar, Mateo; Puebla-Aldama, David; Barragán-Martínez, María del Pilar; Jurado-Hernández, Merly Y.; García-César, Marisol; Rojas, María B. Torres; García-Treminio, Carlos; Roldan-Valadez, Ernesto title: Severe pulmonary hypertension: An important sequel after severe post-acute COVID-19 pneumonia date: 2021-09-30 journal: Curr Probl Cardiol DOI: 10.1016/j.cpcardiol.2021.101004 sha: bfe45677787fb18bef041933a8426ae29801b566 doc_id: 1037064 cord_uid: jlg8xvc3 nan One of the complications of severe pneumonia due to novel coronavirus disease-2019 and ARDS is pulmonary fibrosis 1, 2 ; it is estimated that it affects around a third of hospitalized patients with Severe Acute Respiratory Syndrome Secondary to Coronavirus -2 (SARS-COV-2) 3 . A potential role for anti-fibrotic therapies is suggested based on anecdotal evidence and a proposed similarity in the mechanism of post-COVID- 19 interstitial lung disease (ILD) with idiopathic pulmonary fibrosis (IPF), hence clinical trials are underway, and we await their results 4, 5 . The second complication of infection is usually pulmonary hypertension (PH); the incidence of PH is reported as 15% 6 , although a real prevalence is very difficult to assess; Furthermore, the pathophysiology of the development of PH could be multifactorial due to sequelae of ILD (group 3), associated to chronic thromboembolic pulmonary hypertension (CTEPH) (group 4), myocardial involvement (group 2) and more recently to direct damage of the vessel wall (group 1) 7,8 . A 58 year-old woman with significant relevant medical history of controlled systemic hypertension and history of exposure to wood smoke in childhood, with no other important antecedents, attended our ILD-PH clinic at the General Hospital of Mexico with the chief complain of progressively worse dyspnea on exertion 3 months post severe COVID-19 pneumonia. On her initial evaluation, he was on supplemental oxygen use at 4 liters/min, BMI 26.9, central and peripheral cyanosis, generalized decreased breath sounds, diffuse bilateral crackles, voice transmission, and vocal vibrations without alterations. Cardiac auscultation was remarkable for regular rhythm and rate, and fixed split of S2 on the pulmonary foci. Upper extremities with cyanosis, without clubbing. Lower extremities with evidence of chronic venous insufficiency and edema. Arterial blood gases at room air were performed: bpm, heart axis to the right, and data suggestive of RV pressure overload. Comprehensive pulmonary function tests (PFTs)with bronchodilator challenge reports a suggestive pattern of restriction (Fig 1A-1B) . Six-minute walk test resulted in 192 meters walked, interrupted at minute 4 due to dyspnea and fatigue (Borg scale) of 10 out of 10, respectively. Computed tomographic angiogram (CTA) of the chest showed diffuse bilateral reticular infiltrates and traction bronchiectasis 4 with significant pulmonary trunk dilatation (Fig. 1C and 1D ). Transthoracic echocardiogram (TTE) showed dilated right ventricle, TAPSE: 17 mm and AF 20%, left ventricle with concentric remodeling, LVEF 55%, tricuspid valve with mild insufficiency and maximum velocity of 3.17 m/s. Dilated vein cava with a diameter of 2.1 cm with an inspiratory collapse of 40% ( Fig. 2A) . Given her initial remarkable non-invasive work up for PH, it was decided to perform a right heart catheterization (RHC) at rest with a 7 Fr flotation catheter through the right internal jugular vein demonstrated, to have objective diagnosis and documentation of her possible pulmonary arterial hypertension (PAH). Detailed accurate cardiopulmonary hemodynamics, which were remarkable for severe PAH (precapillary), decreased cardiac index (CI) and a significant increase in pulmonary vascular resistance (PVR). Acute Vasodilator challenge test was not performed (Fig. 2B to 2D ). According to data referring to previous epidemics, 70-80% of patients who survived The hypothesis that SARS-CoV-2 has mechanisms that promote the pathogenesis of PAH was recently published and that some individuals infected with this virus become susceptible to developing clinically significant PAH in the future 12 . The hypothesis is based on histological findings of thickened pulmonary vascular walls in cadavers of patients who died of COVID-19; therefore, it is logical to assume that at least a subset of patients infected with SARS-CoV-2 may be predisposed to developing severe PAH in the future 13 . Likewise, ILD will soon be an emerging complication; the mechanism of post-viral pulmonary fibrosis has been extensively studied in other virus-related epidemics such as influenza and SARS, where serum elevations of GFR-B1, a cytokine that is associated with deposition of extracellular matrix proteins, have been observed, stimulation of chemotactic migration of fibroblasts and transition from fibroblasts to myofibroblasts. The prevalence of 6 post-COVID-19 fibrosis will become apparent over time, but early analysis of these patients at hospital discharge suggests that more than a third of recovered patients will develop fibrotic abnormalities 14 . To date, the literature on post-COVID-19 PH is scarce. Salcin et al. described a clinical case of COVID-19 with great affection to the lung parenchyma documented PH six weeks post-discharge by RHC. However, in their description of the above case, investigators did not report detailed numbers of cardiopulmonary hemodynamics performed during RHC; having a significant limitation in regards appropriate WHO categorization criteria in their patient 15 . According to the World Health Organization (WHO), PH is classified into five groups 16 Our patient was discharged with home oxygen, aggressive respiratory physiotherapy, as well with PAH specific vasodilator therapies with sildenafil (a specific inhibitor of type-5 phosphodiesterase), given the significant and disproportionate severe PAH in comparison with the degree of pulmonary restriction shown in PFTs. Some research experts in PAH world have described potential clinical and hemodynamic benefits with the use of specific pulmonary vasodilators, particularly in the setting of ILD-associated PH, patients who received inhaled Treprostinil (a prostacyclin analog) had a significant improvement in the 6-minute walk test and functional capacity 17 . It is important to emphasize that large-scale randomized clinical trials, as well as prospective multinational registries, are currently being designed and carried out 18, 19 . On the other hand, pirfenidone was started as a promising anti-fibrotic drug for the management of his diffuse ILD, and the patient will be reassessed in our PH-ILD clinic in the following 8-12 weeks. Pulmonary vascular disorders complicating post-acute COVID-19 syndrome clearly represents a global threat for survivors, which may involve multifactorial physiological components of PH and PAH (e.g., a mix of WHO Group 1, 2, 3 or 4 PH). We strongly believe that a multidisciplinary approach with cardiologists, pulmonologists, dedicated pulmonary vascular disease experts, internists with expertise in vascular medicine and thrombosis, and cardiopulmonary physiotherapists may optimize the care of such complex 8 patients. More-over, such integrated care will be of paramount importance for early detection, of long-term complications like multifactorial PH and PAH. A better understanding of implicating physio pathological mechanisms, predisposing risk factors and long-term evolution of severe post-COVID-19 syndrome will trigger the implementation of effective and efficacious therapies, with the aim of improving quality of life and survival for these patients, which they are at significant morbidity and mortality down the road. Relationship disclosures: Written and informed consent was obtained from the patient and available for review if needed. The authors of this case report vouch for accuracy and integrity of the data provided. There is no conflict of interests Clinical course, and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single center, study Post COVID -19 pneumonia pulmonary fibrosis Pulmonary fibrosis in the aftermath of the COVID-19 era (Review) Antifibrotics in COVID-19 lung disease: Let Us Stay Focused Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy Pulmonary hypertension and right ventricular involvement in hospitalized patients with COVID-19 Evidence of Pulmonary Hypertension after SARS-CoV-2 Infection in Subjects without Previous Significant Cardiovascular Pathology Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Respiratory follow-up of patients with COVID-19 pneumonia Hemodynamic profile of pulmonary hypertension (PH) in ARDS Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19 COVID-19 patients may become predisposed to pulmonary arterial hypertension SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells Post covid 19 pulmonary fibrosis-Is it reversible? Recurrent SARS-CoV-2 infection resulting in acute respiratory distress syndrome and development of pulmonary hypertension: A case report Haemodynamic definitions and updated clinical classification of pulmonary hypertension Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease Pulmonary hypertension in parenchymal lung diseases: Any Future for New Therapies? Online ahead of print. Figure captions/legends: Figure 1: (A): Chest radiograph with peripheral confluent ground glass infiltrate, cardiomegaly. (B): Post-bronchodilator spirometry with a severe restrictive functional pattern. (C): CT showing peripheral septal thickening and traction bronchiectasis Author contributions: Every single coauthor designed, performed research, helped in writing, crafting, editing, and critically reviewing key elements of the manuscript. All coauthors read and approved the final version of the manuscript.